MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial OfficerGlobeNewsWire • 11/21/23
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric PatientsGlobeNewsWire • 11/13/23
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in EuropeGlobeNewsWire • 11/08/23
MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?Zacks Investment Research • 09/29/23
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in AdultsGlobeNewsWire • 09/21/23
MediWound's NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association CongressGlobeNewsWire • 09/11/23
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/05/23
MediWound Reports Second Quarter 2023 Financial Results and Provides Company UpdateGlobeNewsWire • 08/15/23
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III StudyGlobeNewsWire • 08/15/23
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell CarcinomaGlobeNewsWire • 07/10/23
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study DesignGlobeNewsWire • 07/03/23
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023GlobeNewsWire • 06/14/23
MediWound Reports First Quarter 2023 Financial Results and Provides a Company UpdateGlobeNewsWire • 05/30/23